Current and emerging treatment options for myopic choroidal neovascularization

Leila El Matri
Ahmed Chebil
Fedra Kort

Department B of Ophthalmology,
Hedi Rais Institute of Ophthalmology,
Faculty of Medicine of Tunis,
University of El Manar, Tunis, Tunisia

Abstract: Choroidal neovascularization (CNV) is the main cause of visual impairment in highly myopic patients younger than 50 years of age. There are different treatments for myopic CNV (mCNV), with 5- to 10-year outcomes currently. Chorioretinal atrophy is still the most important determinant factor for visual outcome. The purpose of this study is to provide an overview of the current treatments for mCNV, including laser, surgical management, verteporfin photodynamic therapy, and mainly anti-vascular endothelial growth factor therapy. Emerging treatment options are also discussed.

Keywords: myopia, choroidal neovascularization, current treatment, emerging treatment

Introduction

Choroidal neovascularization (CNV) is the main cause of visual impairment in highly myopic patients, often affecting adults of working age, resulting in irreversible central vision loss due to progressive and irreversible chorioretinal atrophy (CRA).\(^1\) CNV occurs in approximately 5%–10% of patients with pathological myopia\(^1\) – at any degree of myopia – and even in eyes without characteristic myopic fundus features.\(^2\)

The overall prevalence of myopic CNV (mCNV) is therefore estimated to be approximately 0.04%–0.05% in the general population.\(^1\) Moreover, the natural history of mCNV is particularly variable, with a poor long-term visual outcome. Yoshida et al\(^3\) investigated the natural history of mCNV and studied the long-term progression pattern of myopic maculopathy. Macular atrophy was described in 90.1% untreated mCNV eyes, with a mean follow-up of 11.8 years. Best-corrected visual acuity (BCVA) in 96.3% eyes was 20/200 or worse at 10-year follow-up. The pathogenesis of mCNV remains unclear and different theories have been suggested: mechanical, heredodegenerative, and hemodynamic changes in choroidal circulation.\(^4\) A possible explanation includes, certainly, the induced hypoxia in the outer retina, which is a large source of vascular endothelial growth factor (VEGF) secretion. Chorioretinal stretching, lacquer crack formation, choroidal thinning, choroidal flow disturbance with reduced flow, choroidal filling delay, atrophy of the retinal pigment epithelium (RPE) and overlying retina, and loss of photoreceptors may all be involved in VEGF release and mCNV formation.\(^4\)

Currently, with 5–10 years of follow-up, it is possible to determine the efficiency of the following different treatment options: laser photocoagulation, verteporfin photodynamic therapy (vPDT), surgical management, and mainly intravitreal anti-VEGF therapy.

The aim of this article is to provide a review of the literature related to mCNV and highlight the current and emerging treatment options.
Current treatment options for myopic choroidal neovascularization

Various approaches have been explored to treat myopic choroidal neovascularization (Table 1), which are as follows:

Laser photoocoagulation

For a long time, laser photoocoagulation was the only treatment for extrafoveal mCNV. However, laser is not indicated in subfoveal mCNV. Laser scar expansion and recurrence of CNV are the most important complications. Therefore, laser photoocoagulation has been currently discontinued and replaced with more effective treatments.

Surgical management

Surgical treatments for subfoveal CNV were tried before PDT or antiangiogenic drugs were introduced. They include CNV removal, limited macular translocation, or macular translocation with 360-degree retinectomy (MT360).

Surgical removal of mCNV

Myopic CNV is located under the retina but anterior to the RPE. Thus, the neovascular membrane could be removed with relative preservation of the underlying RPE and stabilization of vision. The integrity of the RPE and the choriocapillaris plays a fundamental role in determining the final visual prognosis following submacular surgery. Surgical excision of subfoveal CNV has been tried in a few studies. Short-term visual acuity (VA) improvement was observed in approximately 50% of the cases.

Macular translocation

Macular translocation (MT) consists of displacing the neurosensory retina of the fovea to a new location along with the normal RPE–Bruch’s membrane–choriocapillaris complex. Thus, the subfoveal lesion is converted to an extrafoveal one, allowing other modalities of treatment without damaging the fovea. Two techniques – limited MT and MT360 – have been performed in the past decade with controversial results. Better results have been reported for limited MT than for surgical removal but with a high rate of recurrences. Unlike surgical excision, MT surgery preserves damage to the RPE–choriocapillaris complex. Specific complications associated with MT include mainly retinal detachments, macular holes, choroidal hemorrhages, and recurrences. Binocular viewing altered by torsional deviations may limit the final visual outcome. The clinical efficacy of MT for mCNV remains uncertain because of the lack of randomized studies. This operation is rarely performed because of the difficult surgical procedures and complications. Nonetheless, in very select cases of mCNV refractory to anti-VEGF therapy, MT may be useful. Recently, Sakimoto et al have reported the long-term effects of MT in a large consecutive case series of 60 eyes with mCNV that underwent MT (mean follow-up period: 76.3 months). They showed that the logarithm of the minimum angle of resolution (logMAR) BCVA values at 1 year, 3 years, and 5 years postoperatively significantly ($P<0.001$) improved to 0.54 at 1 year and then remained stable. MT for mCNV maintained the improvement in VA for $>5$ years. However, postoperative complications and progression of CRA due to myopia still seem to limit the visual improvement after MT for mCNV.

Thus, surgical removal of mCNV may be beneficial in selected patients, but this technique is highly dependent on the surgeon’s ability.

Photodynamic therapy

PDT (Visudyne; QLT Inc, Vancouver, BC, Canada) is the only approved treatment for subfoveal mCNV. The verteporfin in photodynamic therapy (VIP) study, a randomized, double-masked, placebo-controlled clinical trial, demonstrated stabilization of VA in 72% of the eyes with subfoveal mCNV treated with PDT over a period of 12 months. Unfortunately, there was no statistically significant benefit in the visual outcome at 24 months.

Many other studies have reported similar outcomes, with BCVA remaining nearly unchanged at 2 and 3 years. Hayashi et al prospectively followed for 4 years 60 mCNV eyes treated with vPDT. CRA developed in 70% of the eyes at 4 years. The BCVA did not change significantly after PDT. Coutinho et al followed prospectively, for 5 years, 45 mCNV eyes treated with PDT. VA stabilized or improved in 65% of the eyes after 24 months, with no significant VA change between month 24 and month 60. Recently, Varano et al evaluated and compared the effects of PDT in eyes with subfoveal and juxtafoveal CNV with 10-year follow-up. Prevalence and extension of CRA were greater in eyes with subfoveal CNV compared to eyes with juxtafoveal CNV. These results confirm the limited long-term effectiveness of PDT in subfoveal mCNV. This fact may probably be explained by differences in the retinal structure of the central foveal and the juxtafoveal areas. Besides, PDT worsens CRA and, therefore, the long-term visual prognosis of mCNV.

Age at onset of mCNV is the most important factor affecting the final visual outcome following PDT treatment.
## Table 1 Summary of published studies on treatment for myopic choroidal neovascularization

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of eyes</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hamelin et al^8</td>
<td>32</td>
<td>Macular translocation versus surgical removal of CNV</td>
<td>14±15 months</td>
<td>BCVA was statistically better after macular translocation than after surgical removal</td>
</tr>
<tr>
<td>Fujikado et al^9</td>
<td>11</td>
<td>Foveal translocation with 360-degree retinotomy</td>
<td>6.2 months</td>
<td>Vision improved in eight eyes, was unchanged in two eyes, and worsened in one eye. Seven of 11 eyes (64%) had a final visual acuity of 20/50 or better</td>
</tr>
<tr>
<td>Yamada et al^10</td>
<td>32</td>
<td>Full macular translocation</td>
<td>1 year</td>
<td>The final VA was significantly better in mCNV than in exudative age-related macular degeneration</td>
</tr>
<tr>
<td>Sakimoto et al^11</td>
<td>60</td>
<td>Full macular translocation</td>
<td>5 years</td>
<td>BCVA values at 1, 3, and 5 years postoperatively significantly improved (P&lt;0.001) to 0.54 at 1 year and then remained stable</td>
</tr>
<tr>
<td>Hayashi et al^14</td>
<td>43</td>
<td>PDT</td>
<td>1 year</td>
<td>The BCVA improved by more than two Snellen lines in 16.3%, decreased in 14%, and remained stable in 69.7%</td>
</tr>
<tr>
<td>Verteporfin in photodynamic therapy (VIP) study^12</td>
<td>120</td>
<td>PDT</td>
<td>2 years</td>
<td>Stabilization of VA in 72%; there was no statistically significant benefit in the visual outcome at 24 months</td>
</tr>
<tr>
<td>Chen et al^13</td>
<td>33</td>
<td>PDT</td>
<td>2 years</td>
<td>Improvement was much more evident in the younger group, although it was not statistically significant at every follow-up time point</td>
</tr>
<tr>
<td>Hayashi et al^16</td>
<td>46</td>
<td>PDT</td>
<td>4 years</td>
<td>The BCVA did not change significantly</td>
</tr>
<tr>
<td>Coutinho et al^17</td>
<td>43</td>
<td>PDT</td>
<td>5 years</td>
<td>VA stabilized or improved in 65% of the eyes after 24 months, with no significant VA change between month 24 and month 60</td>
</tr>
<tr>
<td>Varano et al^18</td>
<td>19</td>
<td>PDT</td>
<td>10 years</td>
<td>Eyes with subfoveal CNV progressively worsened, while in the eyes with juxtafoveal CNV (63%), BCVA improved</td>
</tr>
<tr>
<td>Yamamoto et al^23</td>
<td>11</td>
<td>IVB</td>
<td>153 days (range: 35–224)</td>
<td>VA improved by a mean of +3.5 lines (range: −1 to +8 lines)</td>
</tr>
<tr>
<td>Sakaguchi et al^24</td>
<td>8</td>
<td>IVB</td>
<td>3–7 months</td>
<td>The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%)</td>
</tr>
<tr>
<td>Scupola et al^21</td>
<td>15</td>
<td>IVB</td>
<td>1 year</td>
<td>The change in BCVA at 1, 6, and 12 months was statistically significant (P&lt;0.05). Eight eyes (53.3%) had BCVA improved by ≥2 lines at 1-year follow-up; six eyes (40%) had an improvement of ≥3 lines. Seven patients (46.7%) had stable vision 12 months after treatment</td>
</tr>
<tr>
<td>Ruiz-Moreno et al^24</td>
<td>19</td>
<td>IVB</td>
<td>2 years</td>
<td>BCVA gain decreases and was no longer significant by the end of the second year</td>
</tr>
<tr>
<td>Hayashi et al^25</td>
<td>75</td>
<td>IVB</td>
<td>2 years</td>
<td>BCVA in eyes with a subfoveal CNV was not significant. BCVA in eyes with nonsubfoveal CNV was significantly improved</td>
</tr>
<tr>
<td>Voykov et al^26</td>
<td>21</td>
<td>IVB</td>
<td>2 years</td>
<td>Mean logMAR BCVA improved from 0.64 at baseline to 0.55 after 1 year (P&lt;0.02) and remained at 0.55 at 2 years (P&lt;0.02)</td>
</tr>
<tr>
<td>Nakanishi et al^26</td>
<td>23</td>
<td>IVB</td>
<td>2 years</td>
<td>BCVA improved after 1 month (P&lt;0.001); the improvement was maintained at 24 months, (P&lt;0.005)</td>
</tr>
<tr>
<td>Gharbiya et al^27</td>
<td>20</td>
<td>IVB</td>
<td>2 years</td>
<td>BCVA improved significantly (P&lt;0.05)</td>
</tr>
<tr>
<td>Peiretti et al^41</td>
<td>21</td>
<td>IVB</td>
<td>4 years</td>
<td>71.4% of the eyes demonstrated an improvement of ≥1 line on the Snellen chart, 14.3% showed and 14.3% lost one line</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Number of eyes</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oishi et al&lt;sup&gt;42&lt;/sup&gt;</td>
<td>22</td>
<td>IVB</td>
<td>4 years</td>
<td>BCVA improved after 1, 2, and 3 years. The effect slightly declined to marginally nonsignificant levels after 4 years</td>
</tr>
<tr>
<td>Liang et al&lt;sup&gt;44&lt;/sup&gt;</td>
<td>9</td>
<td>posterior sub-Tenon injection of bevacizumab</td>
<td>77.56 weeks</td>
<td>BCVA improved by a mean of -0.38 logMAR (&gt;3 lines)</td>
</tr>
<tr>
<td>El Matri et al&lt;sup&gt;10&lt;/sup&gt;</td>
<td>80</td>
<td>PDT versus IVB</td>
<td>1 year</td>
<td>In the IVB group, BCVA was significantly better at 3 months and 6 months than at baseline, but not at 12 months; in the PDT group, mean BCVA was positively improved at 3 months and 6 months, which was not significantly different from that at baseline, then decreased at 12 months</td>
</tr>
<tr>
<td>Baba et al&lt;sup&gt;22&lt;/sup&gt;</td>
<td>24</td>
<td>PDT versus IVB</td>
<td>2 years</td>
<td>The BCVA did not change after PDT but was significantly improved after IVB</td>
</tr>
<tr>
<td>Ikuno et al&lt;sup&gt;22&lt;/sup&gt;</td>
<td>30</td>
<td>PDT versus IVB</td>
<td>2 years</td>
<td>IVB provides a significantly better BCVA than PDT for mCNV over the long term</td>
</tr>
<tr>
<td>Parodi et al&lt;sup&gt;6&lt;/sup&gt;</td>
<td>54</td>
<td>IVB versus PDT versus laser</td>
<td>2 years</td>
<td>IVB offers the best functional results during a 2-year follow-up</td>
</tr>
<tr>
<td>Silva et al&lt;sup&gt;15&lt;/sup&gt;</td>
<td>26</td>
<td>IVR</td>
<td>6 months</td>
<td>VA improved significantly at 1 month, 3 months, and 6 months</td>
</tr>
<tr>
<td>Tufail et al&lt;sup&gt;30&lt;/sup&gt; (REPAIR)</td>
<td>65</td>
<td>IVR</td>
<td>1 year</td>
<td>BCVA improved after 1 year</td>
</tr>
<tr>
<td>Lai et al&lt;sup&gt;66&lt;/sup&gt;</td>
<td>16</td>
<td>IVR</td>
<td>1 year</td>
<td>At 1 month and 12 months, the mean BCVA improved significantly</td>
</tr>
<tr>
<td>Silva et al&lt;sup&gt;17&lt;/sup&gt;</td>
<td>34</td>
<td>IVR</td>
<td>1 year</td>
<td>BCVA improved to 12-month follow-up, and the difference was statistically significant</td>
</tr>
<tr>
<td>Calvo-Gonzalez et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>67</td>
<td>IVR</td>
<td>15.9 months</td>
<td>BCVA improved by 7.8 letters after the first injection, 12.5 letters after three injections, and 12 letters by end of follow-up</td>
</tr>
<tr>
<td>Vadala et al&lt;sup&gt;49&lt;/sup&gt;</td>
<td>40</td>
<td>IVR</td>
<td>18 months</td>
<td>Mean final VA improved in 82.5% of patients</td>
</tr>
<tr>
<td>Franqueira et al&lt;sup&gt;13&lt;/sup&gt;</td>
<td>40</td>
<td>IVR</td>
<td>3 years</td>
<td>High proportion of patients gaining or stabilizing BCVA at a 3-year follow-up</td>
</tr>
<tr>
<td>Freitas-da-Costa et al&lt;sup&gt;15&lt;/sup&gt;</td>
<td>67</td>
<td>IVR</td>
<td>5 years</td>
<td>BCVA was significant at 2 years, and this gain remained significantly stable for 5 years</td>
</tr>
<tr>
<td>Wolf et al&lt;sup&gt;19&lt;/sup&gt; (RADIUSANCE)</td>
<td>277</td>
<td>IVR versus PDT</td>
<td>1 year</td>
<td>IVR provided superior BCVA gains versus PDT up to month 3. Over 12 months, individualized ranibizumab treatment was effective in improving and sustaining BCVA</td>
</tr>
<tr>
<td>Iacono et al&lt;sup&gt;33&lt;/sup&gt;</td>
<td>55</td>
<td>IVB versus IVR</td>
<td>18 months</td>
<td>IVR achieved greater efficacy than IVB and the IVR subgroup achieved a faster central macular thickness</td>
</tr>
<tr>
<td>Ruiz-Moreno et al&lt;sup&gt;55&lt;/sup&gt;</td>
<td>92</td>
<td>IVB versus IVR</td>
<td>4 years</td>
<td>IVB and IVR are effective therapies and show similar clinical effects; VA gain is maintained at 4-year follow-up</td>
</tr>
<tr>
<td>Rinaldi et al&lt;sup&gt;58&lt;/sup&gt;</td>
<td>20</td>
<td>IVP</td>
<td>48 weeks</td>
<td>After IVP, a significant decrease in foveal thickness occurred and at the end of follow-up, CNV closure was obtained in all eyes. An improvement of functional parameters was recorded in all patients</td>
</tr>
<tr>
<td>Kitagawa et al&lt;sup&gt;59&lt;/sup&gt;</td>
<td>31</td>
<td>IVP</td>
<td>1 year</td>
<td>VA and retinal sensitivity were maintained, while metamorphopsia was improved 1 year after IVP</td>
</tr>
<tr>
<td>Kitagawa et al&lt;sup&gt;60&lt;/sup&gt;</td>
<td>28</td>
<td>IVP versus IVB</td>
<td>1 year</td>
<td>Changes in VA at 1 year did not differ significantly between IVB and IVP; IVB improved mean retinal sensitivity with fewer injections than IVP</td>
</tr>
</tbody>
</table>

**Abbreviations:** BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; IVR, intravitreal ranibizumab; logMAR, logarithm of the minimum angle of resolution; mCNV, myopic choroidal neovascularization; PDT, photodynamic therapy; REPAIR, Ranibizumab for treatment of CNV secondary to Pathological myopia: An Individualized Regimen; VA, visual acuity.
In fact, PDT may induce greater damage in elderly subjects who already have choriocapillaris atrophy secondary to longer evolution of myopic retinopathy and/or to age-related choroidal vascular sclerosis.19

In conclusion, all studies show that visual improvement is significant at 1 year after PDT.18 There is no significant change thereafter. Better results are obtained in younger patients.20,21 However, PDT is still a convenient option, especially for patients with juxtafoveal mCNV and when anti-VEGF therapy is unsuitable or may not be feasible.22

Anti-VEGF therapy

Anti-VEGF drugs are currently the “gold standard” for the treatment of mCNV from different causes including high myopia. Intravitreal anti-VEGF is actually recommended as the first-line treatment for mCNV.

Treatment with intravitreal anti-VEGF injection in mCNV was first published in 2007.23 Thereafter, many publications were reported despite the widely “off-label” use of these drugs in mCNV. Nonetheless, all the studies universally demonstrated that intravitreal injections of anti-VEGF agents are efficacious for managing mCNV, improving the functional and anatomical outcomes.23,24 In 2014, ranibizumab was approved for treatment of subfoveal mCNV.

Treatment with bevacizumab

In 2005, Nguyen et al25 reported the results of eyes with subfoveal mCNV treated with systemic bevacizumab (Avastin®; Genentech/Roche). Then intravitreal bevacizumab (IVB) was tested, with no apparent retinal toxicity.26

Yamamoto et al27 and Sakaguchi et al28 were the first to report the treatment of subfoveal mCNV with IVB. Encouraging short-term results and no ocular or systemic side effects were reported in their small case series.

Several articles cited by Silva29 reported on the outcome of IVB at 1-year follow-up. The initial therapeutic protocol was three consecutive, monthly IVB injections for some authors, while for others, only a single IVB injection was used as initial treatment followed by pro re nata injections (PRN). In all studies, the statistically significant visual improvement of two lines or more was sustained at 12 months. Wang and Chen,21 in a systematic review and meta-analysis, compared two groups: three monthly injections (3+ PRN group) and a single injection (1+ PRN group). They did not find significant difference in retinal thickness between the two groups within 12 months. In addition, the 1+ PRN group required 1.37 fewer injections than the 3+ PRN group within 12 months.

Thus, for treating mCNV, one single injection followed by PRN seems to be the best choice. This regimen may decrease the total number of injections and reduce the impact of pan inhibition of VEGF on retinal neuron survival.29

Moreover, a functional improvement was registered in microperimetry studies at 6 months and 12 months.30,31 Scupola et al showed improvement of macular sensitivity and fixation stability 1 year after IVB for mCNV, advocating a stable and progressive macular function recovery.31

Subsequently, studies with 2-year follow-up have reported favorable visual outcomes after IVB,32-37 with improvement of visual acuity by two Early Treatment Diabetic Retinopathy Study (ETDRS) lines. But the results of these studies were controverted because other authors have reported that the visual improvement became nonsignificant after 2 years of follow-up. Thus, Baba et al32 reported that the BCVA was significantly improved at 12 months and at 24 months. In contrast, El Matri et al38 reported that 12 months after starting treatment with bevacizumab, the gain in BCVA was no longer significant. Calvo-Gonzalez et al39 and Ruiz-Moreno and Montero40 also found that after 2 years, the gain in BCVA with anti-VEGF therapy was no longer significant.

The variability of results at 2-year follow-up may be explained by the small sample sizes and the CNV location. In fact, the great majority of studies have included both subfoveal and juxtafoveal mCNV. About 30% of eyes had nonsubfoveal location at presentation, and the natural history of juxtafoveal CNV is not well known. For Hayashi et al41 the results of IVB are different in eyes with a subfoveal CNV from that of eyes with nonsubfoveal CNV. The BCVA was significantly improved after 2 years of follow-up in eyes with nonsubfoveal CNV, while there was no significant difference in eyes with subfoveal CNV. Thus, for eyes with nonsubfoveal CNV, IVB might be a good treatment option. Parodi et al42 obtained similar results on extrafoveal mCNV and, interestingly, no patient experienced a foveal involvement during the follow-up.

More recently, Peiretti et al43 reported the results of a 4-year study of IVB for the treatment of mCNV. This study showed maintenance or improvement of vision in about 85% of the eyes with mCNV. These results are consistent with those reported in previous short-term studies. The best number of IVB injections needed to achieve mCNV closure is not predictable; however, 2–15 IVB injections were applied per eye. Moreover, Ruiz-Moreno and Montero44 clearly demonstrated the efficacy of intravitreal injections of anti-VEGF
El Matri et al in their relatively large case series and showed that VA gain was maintained at 4 years through a mean total number of 4.9 IVB (range: 1–29).

For Oishi et al also, IVB for mCNV is effective for vision improvement in the long term. However, the effect rather declined to slightly nonsignificant levels after 4 years. In fact, visual improvement is restricted by the frequent development or enlargement of CRA. Yoshida et al reported that in the natural course of mCNV, 3 years after disease onset, VA levels had deteriorated continuously and continued to do so for at least another 7 years. This visual deterioration may be due to the development of myopic CRA, which also might decrease the efficacy of anti-VEGF agents for improving VA (Figure 1).

Because of scleral thinning in high-myopic patients, especially at the posterior pole, it was hypothesized that a posterior sub-Tenon injection of bevacizumab (PSTB) may be an effective alternative route of delivery due to the significant penetration by bevacizumab through the sclera to reach the CNV zone. Liang et al evaluated the effectiveness of PSTB treatment for mCNV: 88.89% of eyes remained at baseline VA or had visual improvement, 66.7% of eyes improved by at least two lines, and 44.4% of eyes showed improvement of at least three lines. Their results are comparable with, or even better than, those reported previously for IVB injections, showing that the effect of PSTB in mCNV is promising.

Treatment with ranibizumab
Ranibizumab (Lucentis™; Novartis Pharma AG, Basel, Switzerland, and Genentech Inc, South San Francisco, CA, USA) has been specifically designed for ocular use. It is the only licensed anti-VEGF therapy for treatment of mCNV.

Intravitreous ranibizumab (IVR) showed apparently superior results when compared with PDT for juxtafoveal and subfoveal mCNV. Silva et al reported the first results of IVR for mCNV following a PRN regimen since the first injection. At 3 months after IVR injection, VA improved by one or more lines in 65% of eyes and all eyes had stable or improved vision at 3 months. These short-term results seemed to be similar to those of other studies, cited by Silva which used IVB for mCNV. Many authors have reported the results of IVR at 1-year follow-up with a VA

Figure 1 Development of CRA around the subfoveal CNV treated with IVB injection in the right eye of a 34-year-old woman with a refractive error of −10.0 diopters and axial length of 27.8 mm.

Notes: (A) Fundus photograph of the right eye shows small fibrovascular membrane 1 month after IVB; (B) 1 year after IVB, the right fundus shows a regressed CNV with CRA around; (C) 3 years after IVB, the right fundus shows a large CRA; (D) 5 years after IVB, the right fundus shows a larger central area of CRA.

Abbreviations: CNV, choroidal neovascularization; CRA, chorioretinal atrophy; IVB, intravitreal bevacizumab.
improvement of three or more lines in 24%–46.8% of cases. Angiographic closure occurred at 3 months in 93.8% of the eyes.\textsuperscript{45} During the 12-month follow-up, a mean of 3.6 intravitreal injections was performed.

Treatment regimens with and without loading dose were evaluated in different studies. Lai et al\textsuperscript{46} obtained a significant VA gain at 1 year using a loading dose of three monthly injections. Of the 16 patients, 75% gained vision and only one patient needed retreatment.

Other authors reported, in prospective studies, similar good results with no loading dose, achieving a significant VA improvement from baseline.\textsuperscript{39,47,48}

Actually, the use of ranibizumab for treatment of mCNV is supported by data from phase II (Ranibizumab for treatment of CNV secondary to Pathological myopia: An Individualized Regimen or REPAIR) and phase III (RADIANCE) trials.\textsuperscript{49–51}

REPAIR is a large, phase II, open-label, single-arm, multicenter, nonrandomized study of 65 patients from the UK. It indicated that ranibizumab was effective in improving vision and preventing vision loss with a median of 3 injections over 12 months.\textsuperscript{50}

RADIANCE, a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia, compared the efficacy and safety of ranibizumab in two groups treated by IVR with two different PRN schedules to a third group treated with vPDT (N=227).\textsuperscript{49}

The first group treated with PRN ranibizumab was guided by VA stabilization criteria and the second group was guided by disease activity criteria. RADIANCE showed that patients treated with both PRN regimens of ranibizumab provided superior BCVA gains in comparison with patients treated with vPDT at 3 months. Retreatment criteria did not affect the 6-month results in the ranibizumab treatment groups. At 12 months, irrespective of retreatment criteria, ranibizumab was effective in improving and sustaining BCVA and was generally well tolerated in patients with mCNV.\textsuperscript{49} Moreover, patients who were previously treated by vPDT could still gain vision when they were switched to ranibizumab. Nevertheless, patients initially treated by vPDT and later switched to IVR did not achieve the same visual gains as those treated initially with IVR. Anatomical outcome improvements were observed with both IVR and vPDT.\textsuperscript{49} RADIANCE also revealed significant improvements in several quality-of-life parameters for patients treated with ranibizumab compared with vPDT, which were maintained through to 12 months.\textsuperscript{52}

Franqueira et al\textsuperscript{53} published the 3-year follow-up of a prospective study that included 40 eyes with mCNV treated with ranibuzimab. The mean VA improved significantly from 55.4 ETDRS letters at baseline to 63.4 letters at 36 months. Thirty-five percent of the patients gained ≥3 lines at 36 months. A mean of 4.1 injections was used in the first year, 2.4 in the second year, and 1.1 in the third year.

Iacono et al\textsuperscript{44} reported the results of one of the largest randomized studies of IVB versus IVR in treatment-naïve mCNV. VA improved significantly after anti-VEGF therapy and improvement remained statistically significant at 18 months. Moreover, there was no significant difference in VA between eyes treated with bevacizumab or ranibizumab at all time points.

Ruiz-Moreno et al\textsuperscript{55} demonstrated the long-term efficacy of intravitreal injections of both bevacizumab and ranibizumab. They showed that the mean number of letters read was 46.1 at baseline, 55.5 at 1 year, 50.1 at 2 years, 54.2 at 3 years, and 53.1 at 4 years.

Recently, Freitas-da-Costa et al\textsuperscript{56} reported the long-term results of anti-VEGF therapy in mCNV. The mean change from baseline BCVA was significant at 2 years (+8.6 letters; \(P<0.001\)) and this gain remained significantly stable for a period of 5 years. The mean number of injections performed during the first year was 5.2, becoming lower in subsequent years (\(P<0.001\)).

In conclusion, when antiangiogenic drugs are used to treat mCNV, the suggested protocol could be an initial injection of 0.05 mL of either 1.25 mg bevacizumab or 0.5 mg ranibizumab, followed by a monthly evaluation of VA using optical coherence tomography (OCT), with additional treatments in case of loss of BCVA, evidence of CNV activity on OCT, or persistent leakage of CNV shown on fluorescein angiography.\textsuperscript{55} A favorable long-term outcome can be achieved with a relatively small number of injections in cases of mCNV.

**Treatment with pegaptanib**

Intravitreal pegaptanib (IVP) was also evaluated in mCNV. The first case treated successfully with IVP injections, a young patient with mCNV refractive to laser photocoagulation and PTD, was reported by Benett and Yee\textsuperscript{57} in 2007. Then, Rinaldi et al\textsuperscript{58} and Kitagawa and Yuzawa\textsuperscript{29} reported 1 year or less outcome of intravitreal pegaptanib. The initial treatment protocol consisted of three monthly consecutive injections. The findings demonstrate that the selective inhibition of VEGF-165 isoform by IVP injections is an effective treatment for mCNV.

One-year treatment outcomes of intravitreal injections of pegaptanib sodium and bevacizumab for mCNV were...
Although changes in VA at 1 year did not differ significantly between the two groups, bevacizumab improved mean retinal sensitivity with fewer injections than pegaptanib, suggesting that bevacizumab may be more effective than pegaptanib for mCNV.

### Treatment with aflibercept (VEGF trap-eye)

Aflibercept (Eylea®; Regeneron Pharmaceutical Inc and Bayer) is the most recent member in the anti-VEGF arsenal. Its efficacy and safety for mCNV was evaluated in the ongoing phase III, multicenter, randomized, sham-controlled, 12-month MYRROR study in Asian patients (N=121; NCT01249664). A single intravitreal aflibercept injection is administered, followed by a PRN regimen. After 6-month follow-up, a 12.1-letter improvement in BCVA is reported, compared with a 2-letter loss in those receiving sham injections. BCVA gains are maintained up to 12 months, as mentioned by Wong et al.42

In conclusion, once mCNV is diagnosed, prompt treatment is suggested with a single intravitreal injection of anti-VEGF, followed by PRN dosing. Then, patients should be followed monthly to monitor the signs of activity of mCNV, seeking by questioning a decrease in vision, new or persistent metamorphopsia, and detecting disease activity by both clinical evaluation such as new hemorrhage on fundus examination and relevant imaging: OCT and/or angiography showing intraretinal or subretinal fluid or persistent leakage. Spectral domain OCT is actually the most useful tool for evaluating neovascular activity. A decrease in BCVA alone is not sufficient. It could indicate additional pathologies, such as myopic traction maculopathy (foveoschisis), macular hole, retinal tears, and rhegmatogenous detachments.39

If there is a disease activity, another intravitreal injection of anti-VEGF is performed. A favorable long-term outcome can be achieved with a notably lower number of injections in cases of mCNV compared to other conditions such as neovascular age-related macular degeneration (AMD). As the long-term safety and efficacy of anti-VEGF treatment of mCNV are unknown, we must not forget that, because VEGF has an important role in neuroprotection and retinal development also,36,37 anti-VEGF treatment may produce retinal impairment after a long period of administration. Moreover, we must not forget the likely risk of retinal detachment in myopic eyes submitted to repeated intravitreal injections. Intravitreal injection of anti-VEGF should be given only in case of resumption of activity of the mCNV. If there is no disease activity, patients should be controlled monthly the first 3 months. Then, visits will be considered every 3 months for the first year.

Whether ranibizumab, bevacizumab, or aflibercept should be chosen is unknown. They are all effective. The availability of intravitreal bevacizumab, an inexpensive drug, provides an opportunity to prevent VA loss in low-income countries where the cost of ranibizumab or aflibercept is excessively high.

Therefore, regardless of the selected treatment, the development of CRA around the mCNV is a specific complication threatening vision, requiring prevention for maintaining the long-term vision. In fact, it is still unknown whether anti-VEGF treatment could slow down the atrophy development in myopic eyes.

Recently, Farinha et al.51 analyzed the long-term progression of myopic maculopathy and functional outcome in eyes treated for mCNV and in eyes without CNV. Three different therapeutic approaches – PDT, IVR, and PDT + IVR – were compared. There were no significant differences in morphological and functional outcomes among the groups. The morphological changes in all treated eyes were more likely to be linked with the natural progression of the myopic maculopathy than with the type of treatment performed.

Calvo-Gonzalez et al.39 also found that after 2 years of treatment with IVR for mCNV, 70.2% of the eyes developed CRA around the regressed CNV. Oishi et al.42 reported, 4 years after IVB, development or enlargement of CRA in 72.7% of the eyes. Moreover, Hayashi et al.40 reported that 74.1% of untreated eyes developed macular atrophy, and after 5 years, the prevalence was 96.3%. In eyes treated for mCNV, the area of macular atrophy increased significantly until the final evaluation. So, this confirms that CRA can develop and enlarge long after CNV has regressed not only in untreated eyes but also in eyes treated with PDT and/or anti-VEGF and may be responsible for the progressive reduction of treatment efficacy in the long term.29,39,45

Multivariate regression analysis showed that age, degree of myopia, presence of staphyloma, and a greater baseline central area of macular atrophy were predictive of greater areas of macular CRA in the long term.12,30,61,62

### Emerging treatments

Promising investigations that are being conducted in AMD–CNV could be extrapolated to mCNV management.63 Emerging treatments may include new molecules acting on different parts of the VEGF cascade, antiangiogenic molecules of greater duration of action, sustained-release ophthalmic drug formulations, and the use of a small molecule that neutralizes the VEGF receptor.
delivery systems, new surgical approaches such as cell transplantation (retinal pigment epithelial cell transplantation) and transplantation of retina and choroid, or the use of radiation in combination with or without intravitreal therapies.64

New molecules acting on different parts of the VEGF cascade can be classified as follows:

- Small interfering RNA (siRNA):65,66 siRNA 027 (AGN211745) targets VEGF receptor (VEGFR)-1 on the endothelial cells and siRNA PF-04523655 (RED14) inhibits the expression of hypoxia-induced gene RTP801.
- Anti-VEGF agents: other antagonists to the VEGF pathway are also being evaluated. 1) Sphingosine-1-phosphate (S1P) antibody: The RPE cells are a major source of S1P in the retina and S1P is in charge of the pathological angiogenesis, vascular permeability, inflammatory responses, and fibrosis associated with neovascular AMD.67 2) Squalamine lactate.68 3) Palomid 529 is an investigational medication involving the immune Akt/mTOR pathway and unique in dissociating both targets of rapamycin complexes TORC1 and TORC2.69 4) KH902 has similar properties as a fibroceptor.70 5) Intravitreal injection of adeno-associated virus-2 vector is being used to deliver an anti-VEGF molecule, sFLT01.71 6) MP0112 is a designed ankyrin repeat protein that specifically binds all VEGF-A isoforms.72 7) Tyrosine kinase inhibitors: vatalanib with activity against the platelet-derived growth factor receptor (PDGFR) and c-Kit receptor kinases;73 and oral pazopanib with activity against VEGFR, PDGFR, and c-Kit.74 8) PDGF antagonists, eg, E10030.

Antiangiogenic molecules with greater duration of action

Drug formulations of greater duration of action are being considered to reduce the frequency of intravitreal injection as well as to reduce the rate of complications. Liposomes are one of the most advanced drug nanocarriers.75

Sustained-release ophthalmic drug delivery systems

In situ injectable polysaccharide cross-linked hydrogel was developed for ocular drug delivery of bevacizumab.76 Intravitreal, liquid, sustained drug delivery system formulated with triamcinolone acetonide in combination with ranibizumab has been evaluated in AMD and has resulted in fewer ranibizumab retreatments. Besides, intraocular injection of triamcinolone acetonide nanoparticles incorporated in thermoreversible gels seems to reduce VEGF expression in neovascular AMD.77

Radiation therapies

The following therapies are explored: proton therapy, stereotactic radiotherapy, and epimacular brachytherapy.

Recently, Chen et al78 reported the 2-year results of a randomized clinical trial on proton beam irradiation for non-AMD–CNV. Myopic CNV constituted the most common diagnosis (52.9% of 51 eyes) among their cases. The authors found that at 24 months, proton beam radiation therapy with either 16 or 24 cobalt gray equivalent is safe, may prevent vision loss, and, in some cases, improve vision in patients with mCNV. The principle of therapy is that radiation can inhibit endothelial cell proliferation, decrease angiogenic cytokine-producing inflammatory cells in CNV complexes, and reduce proliferation of fibroblasts involved in scar formation. Thus, this treatment modality may be considered as an alternative therapy in cases where PDT or intravitreal anti-VEGF treatment may not be feasible. Proton therapy has mainly the benefit of a single cure and the possibility for more selectivity due to the relative resistance of neural tissue to radiation damages and it may be used as an adjunct to anti-VEGF therapy.78

Epimacular brachytherapy was developed to deliver intraocular radiation. The source of beta radiation is placed close to the CNV complex in the macular region and the radiation (24 Gy) is delivered via a pars plana vitrectomy positioning the probe over the CNV lesion (VideON system). This treatment can stabilize neovascular AMD, thus decreasing the requirement for intravitreal anti-VEGF therapy.79

Stereotactic radiotherapy (SRT; iRay system) uses a low-voltage X-ray system with a great advantage of not requiring invasive surgical procedures. The X-ray is collimated into a narrow beam that enables precise targeting limited to the macula. A single dose of SRT significantly reduces intravitreal injections of anti-VEGF in AMD, over a period of 2 years.80

Besides, the role of genetics in the development of myopia and pathological myopia is now obvious based on scientific evidence. It can therefore be assumed that there is a genetic role in the pathogenesis of mCNV. To date, there are no publications on genes associated with mCNV.81 Miyake et al82 reported that VEGF polymorphism influences VA prognosis in highly myopic eyes with CNV within 1 year after anti-VEGF treatment. This association was still observed after removing its confounding effect through CNV size. The rs2010963 polymorphism was not associated with CNV recurrence or CRA progression, which indicates that these changes are not tied to intrinsic factors and may be controllable by improving treatment methods.
Finally, as the best treatment of myopic CNV is still unknown and the long-term visual prognosis is unclear, prevention should be considered. Research investigating and identifying risk factors for the development and progression of high myopia and mCNV must be conducted.

In the future, it will be mandatory both to assess the mechanism underlying chorioretinal atrophy development and enlargement and to establish the best treatment modalities that may prevent VA loss.

Disclosure
The authors report that they have no proprietary interest and have received no grants, funds, or financial support in relation to this study.

References


